About Zepbound®
Class: Brand tirzepatide for weight loss
Brand/Manufacturer: Eli Lilly
Dosing: Weekly subcutaneous (up to 15 mg)
Mean weight loss: 22.5%
Pivotal trial: SURMOUNT-1, SURMOUNT-2
Zepbound® is Eli Lilly's brand-name tirzepatide approved for chronic weight management. SURMOUNT-1 showed 22.5% mean weight loss at 72 weeks. Retail $1,059/month without insurance; LillyDirect offers $349-$549/month direct-to-patient program.
Mechanism of action
Zepbound® acts on the GLP-1 receptor (and GIP receptor in the case of tirzepatide), producing four primary effects: central appetite suppression, delayed gastric emptying, glucose-dependent insulin release, and glucagon suppression. The combined effect on body weight averaged across pivotal trials is 22.5% body weight reduction at the trial endpoint.
Clinical evidence
The pivotal trial supporting Zepbound®'s weight management indication is SURMOUNT-1, SURMOUNT-2. Detailed data including primary and secondary endpoints, population characteristics, and adverse event frequencies is summarized on our clinical research page.
How to access Zepbound® via telehealth
Zepbound® is available through several U.S. telehealth providers. Compounded versions (where applicable) are dispensed by 503A licensed compounding pharmacies and 503B FDA-registered outsourcing facilities. NexLife is our editorial #1 pick for Zepbound® access — see the side panel for details.
FAQ
Is Zepbound® FDA-approved?
The brand-name versions of Zepbound® are FDA-approved for the indications listed above. Compounded versions are not FDA-approved.
How much does Zepbound® cost?
Brand-name Zepbound® typically costs hundreds to over a thousand dollars per month at retail. Compounded equivalents (where available) cost significantly less. See our cost guide for verified May 2026 pricing.